Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Control of Neuropathic Pain Depends on a Schwann Cell Protein

By BiotechDaily International staff writers
Posted on 09 Apr 2013
Image:  Schwann cells (colored purple) forming myelin sheathes (green) around axons (brown) (photo courtesy of David Furness, Wellcome Images).
Image: Schwann cells (colored purple) forming myelin sheathes (green) around axons (brown) (photo courtesy of David Furness, Wellcome Images).
Pain researchers have found that a protein produced by Schwann cells plays a critical role in controlling allodynia (painful response to a stimulus that does not normally elicit pain) and in regulating the recovery of peripheral nerves after injury.

Schwann cells are involved in many important aspects of peripheral nerve biology such as the conduction of nervous impulses along axons, nerve development and regeneration, trophic support for neurons, production of the nerve extracellular matrix, modulation of neuromuscular synaptic activity, and presentation of antigens to T-lymphocytes.

Investigators at the University of California, San Diego (UCSD; USA) recently linked the protein LRP1 (LDL receptor-related protein-1) produced by Schwann cells to the neuropathic pain that occurs when peripheral nerve fibers are damaged or become dysfunctional. LRP1 is an endocytic receptor involved in several cellular processes, including intracellular signaling, lipid homeostasis, and clearance of apoptotic cells. In addition, the encoded protein is necessary for the clearance of secreted amyloid precursor protein and beta-amyloid, the main component of amyloid plaques found in Alzheimer's disease patients. Expression of the LRP1 gene decreases with age and has been found to be lower than controls in brain tissue from Alzheimer patients.

For this study, the investigators genetically engineered a line of mice lacking the gene for production of LRP1. They reported in the March 27, 2013, issue of the Journal of Neuroscience that these mice had abnormalities in axon myelination and in ensheathment of axons by nonmyelinating Schwann cells in Remak bundles (multiple nonmyelinated pain transmitting axons grouped together by Schwann cells). Remyelinated axons were evident 20 days after crush injury in control mice, yet were largely absent in mice lacking the LRP1 gene. In the partial nerve ligation model, mice without LRP1 demonstrated significantly increased and sustained mechanical allodynia and loss of motor function.

These studies identified LRP1 as an essential mediator of normal Schwann cell activity and as a pivotal regulator of the Schwann cell response to peripheral nervous system injury in vivo. "LRP1 helps mediate normal interactions between Schwann cells and axons and, when peripheral nerves have been injured, plays a critical role in regulating the steps that lead to eventual nerve regeneration," said senior author Dr. Wendy Campana, associate professor of anesthesiology at the University of California, San Diego. "When LRP1 is deficient, defects and problems become worse. They may go from acute to chronic, with increasing levels of pain."

The investigators are working to develop small molecule drugs to mimic LRP1 binding to receptors in Schwann cells to improve their health and ability to repair damaged nerve cells. "By targeting Schwann cells and LRP1, I think we can improve cells' response to injury, including reducing or eliminating chronic neuropathic pain," said Dr. Campana.

Related Links:

University of California, San Diego



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.